navitoclax + fludarabine + cyclophosphamide + rituximab

This drug is a **combination therapy** comprised of *navitoclax*, *fludarabine*, *cyclophosphamide*, and *rituximab*. Each component has a distinct mechanism: - **Navitoclax** is a small molecule BH3 mimetic that inhibits anti-apoptotic proteins in the BCL2 family (notably BCL2, BCL-xL, and BCL-w), promoting cancer cell apoptosis. It is primarily under investigation for B-cell malignancies such as chronic lymphocytic leukemia (CLL)[1][2][4]. - **Fludarabine** is a purine analog antimetabolite that inhibits DNA synthesis and induces apoptosis in lymphocytes. - **Cyclophosphamide** is an alkylating agent that cross-links DNA, causing cell death. - **Rituximab** is a monoclonal antibody targeting CD20 on B lymphocytes, leading to cell lysis through immune mechanisms. This combination is evaluated for the treatment of hematological malignancies, especially **CLL**, where synergistic effects and improved response rates have been observed when combining BCL2 inhibition with conventional cytotoxic and immunotherapeutic agents[2][4].